Syverson Strege & Co’s Gilead Sciences GILD Stock Holding History

Syverson Strege & Co’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$447K	Buy	3,208 +103	+3%	+$14.4K	0.11%	85
2025 Q4	$381K	Buy	3,105 +436	+16%	+$53K	0.09%	94
2025 Q3	$296K	Sell	2,669 -284	-10%	-$32.3K	0.07%	116
2025 Q2	$327K	Buy	+2,953	New	+$314K	0.08%	108
2023 Q2	–	Sell	-110	Closed	-$9.13K	–	284
2023 Q1	$9.13K	Buy	+110	New	+$9.11K	﹤0.01%	262

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Syverson Strege & Co's GILD Position: Q1 2026 in Review

Syverson Strege & Co increased its Gilead Sciences (GILD) stake by 3.3% in Q1 2026, buying an estimated $14.4K and bringing the position to 3,208 shares worth $447K. The position accounts for 0.11% of the portfolio, ranked #85.

Syverson Strege & Co first reported a position in GILD in Q1 2023 and has held it in 5 quarters since. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

Syverson Strege & Co held 3,208 shares of Gilead Sciences worth $447K as of Q1 2026.
Syverson Strege & Co bought 103 Gilead Sciences shares in Q1 2026, an estimated $14.4K.
Gilead Sciences made up 0.11% of Syverson Strege & Co's portfolio in Q1 2026, its #85 holding.
Syverson Strege & Co first reported a position in Gilead Sciences in Q1 2023 and has held it in 5 quarters since.
2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Syverson Strege & Co's 13F filing for Q1 2026, filed 4 May 2026.